胰导管腺癌（PDAC）是一种具有潜在发病和早期远处转移且高度致命的恶性肿瘤。代谢重编程是PDAC快速进展的关键，它是细胞生物能的自主变化，由异常基因事件和癌细胞与非癌细胞在纤维化微环境中的信息传递驱动。作为一种有吸引力的治疗靶点，核苷代谢受各种抗代谢药物的调控来进行PDAC的临床治疗。尽管存在诸多挑战，如药物传递效率低和靶向效果差，但代谢修饰和干预正因纳米技术基于药物传递策略的迅速发展而成为PDAC治疗的有前途的策略。本文评述PDAC的代谢特点，并重点介绍纳米医学的发展如何通过调节代谢重编程的关键靶点促进了PDAC的新疗法的发展。版权所有 © 2023年Elsevier B.V.出版。

Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy with insidious onset and early distal metastasis. Metabolic reprogramming, the autonomous changes in cellular bioenergetics driven by aberrant genetic events and crosstalk between cancer and non-cancer cells in the desmoplastic microenvironment, is pivotal for the rapid progression of PDAC. As an attractive therapeutic target, nucleoside metabolism is regulated by various anti-metabolic drugs for the clinical treatment of PDAC. Despite various challenges, such as poor drug delivery efficiency and off-target side effects, metabolic modification and intervention are emerging as promising strategies for PDAC therapy, enabled by the rapid development of nanotechnology-based drug delivery strategies. In this review, we discuss the metabolic characteristics of PDAC and highlight how the development of nanomedicine has boosted the development of new therapeutics for PDAC by modulating critical targets in metabolic reprogramming.Copyright © 2023. Published by Elsevier B.V.